YIDU TECH (02158) announced its interim results for the six months ended September 30, 2025, with revenue reaching approximately RMB358 million, up 8.7% year-on-year. Gross profit rose 14.2% YoY to RMB134 million, while the net loss narrowed by 72% to RMB15.76 million.
The Big Data Platform and Solutions segment generated revenue of RMB153 million, a 14.6% YoY increase, driven by expanded business opportunities from policy tailwinds. The Health Management Platform and Solutions segment recorded revenue of RMB66.6 million, up 30.3% YoY, primarily due to product mix optimization.
As the group’s core algorithm engine, YiduCore continued advancing the development and training of large language models for the medical vertical. Leveraging over 500 billion high-quality tokens, it processed and analyzed nearly 7 billion authorized medical records from more than 1.3 billion patient visits, building a dataset system covering over 98 specialized diseases.
YiduCore’s models won the "Medical NLP Code Auto-Generation Evaluation" championship and "Best Paper Award" at the 11th China Health Information Processing Conference (CHIP 2025) and secured first prize in the healthcare track at the 2025 "Data Factor ×" competition in Jiangxi.
As a key partner in Beijing’s national AI application pilot base for healthcare, YiduCore achieved scaled deployment across medical, pharmaceutical, and health insurance sectors via its "one-base, multi-application" model, delivering end-to-end solutions for "hospitals–pharma–insurance–patients." During the reporting period, the group served 127 top-tier Chinese hospitals and 44 regulatory bodies, cumulatively covering over 10,000 hospitals.
Powered by "data factors × AI technology," YIDU TECH strengthened its intelligent data infrastructure and accelerated large-scale AI applications. Its big-model technology aided multiple hospitals in data governance and research platform upgrades, with clinical studies expanding in oncology, respiratory, and traditional Chinese medicine disciplines. The Doctor Copilot product suite covered full diagnostic workflows, logging over 50,000 single-hospital uses, while the AI mid-platform supported innovative applications in hospitals and aesthetic medicine.
The group served 88 life science clients, including 17 of the top 20 multinational pharmaceutical firms. It achieved breakthroughs in pediatric rare diseases and cell therapy, accelerating approvals for pioneering drugs.
In health management, YIDU TECH maintained dominance in key cities, operating as the primary platform for "Shenzhen Huiminbao" (three consecutive years) and "Beijing Huiminbao" (five consecutive years). "Shenzhen Huiminbao" hit a record 6.15 million enrollees, cumulatively serving over 18 million人次 in three years. Active users completing at least one transaction on its health platform exceeded 22 million, reflecting growing brand loyalty.
Comments